Different studies have evaluated the prognostic effect of ctDNA detection on localized breast cancer, including different subtypes of breast cancer (e.g., HR+/HER2+ breast cancer, triple negative breast cancer, among others). Here, ERBB2 is linked to triple-negative breast carcinoma.